Applicants U.S. Serial No.:

Filed

Page 2

Philip O. Livingston and Friedhelm Helling

08/475,784

June 7, 1995

ganglioside to Keyhole Limpet Hemocyanin or a thereof and a carbohydrate derivative of bark a Ouillaja derivable the from the amounts of such saponaria Molina tree,, conjugated ganglioside and such carbohydrate stimulate or dffective to/ being antibody production in a subject, pharmaceutically acceptable carrier, wherein the ganglioside is selected from the group GD3, GD3 lactone, Oconsisting of GM2, GM3,

acetyl GD3 and GT3.--

--67. (Amended)

A method of preventing or treating a cancer in subject which comprises administering to the subject an effective cancer preventing or the ting amount of the composition of claim **53.--**

--73. (New)

ganglioside comprising a composition conjugated through the ceramide portion of the ganglioside to Keyhole Limpet Hemocyanin or a carbohydrate and а derivati/ve thereof <u>Quillaja</u> of а derivabÅe from bark the saponaria Molina tree, the amounts of such conjugated ganglioside and such carbohydrate being/ effective to stimulate orenhance antibody production in a subject, pharmaceutically acceptable carrier, wherein the conjugation of the ganglioside is through

a ceramide-derived carbon .--

--74. (New)

ganglioside composition comprising Α conjugated through the ceramide portion of the

Applicants : U.S. Serial No.: Filed :

Philip O. Livingston and Friedhelm Helling 08/475,784
June 7, 1995

Filed Page 3

> ganglioside to Keyhole Limpet/Hemocyanin or a carbohydrate thereof and a derivative Ouillaja of a from the bark/ derivable the amounts of such saponaria Molina tree, conjugated ganglioside and such carbohydrate s/timulate orenhance being effective to i∕n a subject, and a antibody production pharmaceutically acceptable carrier, wherein the conjugation of the ganglioside is through a carbon derived from a cleavage of a double ceramide portion the

ganglioside. --

75. (New)

ganglioside composition / comprising a conjugated through the ceramide portion of the ganglioside to/Keyhole Limpet Hemocyanin or a а carbohydrate and thereof € derivative Ouillaja of bark from the derivable saponaria Molina tree, the amounts of such conjugated/ganglioside and such carbohydrate being effective to stimulate or enhance antibody / production in a subject, pharmaceutically acceptable carrier, wherein the confugation of the ganglioside is through a carbon derived from a ceramide double bond to Keyhole Limpet Hemocyanin or a derivative thereof. --

76. (New)

ganglioside ¢omposition comprising a conjugated through the ceramide portion of the ganglioside to Keyhole Limpet Hemocyanin or a carbohydrate thereof and derivative <u>Quillaja</u> of derivable from the bark

Applicants : U.S. Serial No.: Filed : Page 4

Philip O. Livingston and Friedhelm Helling 08/475,784
June 7, 1995

saponaria Molina tree, the amounts of such conjugated ganglioside and such carbohydrate being effective to stimulate or enhance antibody production in a subject, and a pharmaceutically acceptable carrier, wherein the conjugation of the ganglioside involves a ceramide double bond of the ganglioside and a reactive amine group of Keyhole Limpet Hemocyanin or a derivative thereof.--

--77. (New)

ganglioside comprising а composition Α conjugated through the deramide portion of the ganglioside to Keyhole Limpet Hemocyanin or a carbohydrate a thereof and deriva/tive <u> Ouillaja</u> of a bark frøm th∉ derivable saponaria Molina tree, the amounts of such conjugated/ganglioside and such carbohydrate to stimulate or ef/fective being ' antibody production in a subject, and a pharmaceutically acceptable carrier, wherein the conjugation of the ganglioside involves a ceramide double/bond of the ganglioside and an aminolysl group of Keyhole Limpet Hemocyanin or a derivative thereof. --

REMARKS

Claims 53-72 were pending in subject application. Applicants have hereinabove canceled claims 54 and 58 without prejudice to applicants right to pursue the subject matter in a later-filed application. Applicants have hereinabove amended claims 53 and 67. Support for new claims 73-77 may be found <u>inter alia</u> in the specification on page 32, line 1 to page 33, line 10. Applicants contend that this amendment does not involve any issue of new